Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics.
作者信息
Usman N, Blatt L M
机构信息
Research and Development, Ribozyme Pharmaceuticals Inc., Boulder, Colorado 80301, USA.
出版信息
J Clin Invest. 2000 Nov;106(10):1197-202. doi: 10.1172/JCI11631.
Abstract
摘要
相似文献
1
Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics.
J Clin Invest. 2000 Nov;106(10):1197-202. doi: 10.1172/JCI11631.
2
Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors.
Clin Cancer Res. 2000 May;6(5):2094-103.
3
Chemical engineering of RNase resistant and catalytically active hammerhead ribozymes.
Bioorg Med Chem. 1997 Nov;5(11):1999-2010. doi: 10.1016/s0968-0896(97)00144-2.
4
Ribozymes: structure, characteristics and use as potential antiviral agents.
J Hepatol. 1995;22(1 Suppl):57-64.
5
[Alternative treatment to interferon therapy in chronic viral hepatitis].
Gastroenterol Hepatol. 1995 Oct;18(8):430-6.
6
Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes.
Hepatology. 2000 Mar;31(3):769-76. doi: 10.1002/hep.510310331.
7
Ribozyme: a clinical tool.
Clin Chim Acta. 2006 May;367(1-2):20-7. doi: 10.1016/j.cca.2005.11.023. Epub 2006 Jan 19.
8
9
Recent developments in RNA-based strategies for cancer gene therapy.
Curr Opin Mol Ther. 2001 Apr;3(2):116-24.
10
Expanding the catalytic repertoire of ribozymes and deoxyribozymes beyond RNA substrates.
Curr Opin Mol Ther. 2010 Apr;12(2):223-32.
引用本文的文献
1
Enhanced hammerhead ribozyme turnover rates: Reevaluating therapeutic space for small catalytic RNAs.
Mol Ther Nucleic Acids. 2024 Dec 21;36(1):102431. doi: 10.1016/j.omtn.2024.102431. eCollection 2025 Mar 11.
2
Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19).
Arch Microbiol. 2023 Mar 30;205(4):150. doi: 10.1007/s00203-023-03480-5.
3
A modular XNAzyme cleaves long, structured RNAs under physiological conditions and enables allele-specific gene silencing.
Nat Chem. 2022 Nov;14(11):1295-1305. doi: 10.1038/s41557-022-01021-z. Epub 2022 Sep 5.
4
Next RNA Therapeutics: The Mine of Non-Coding.
Int J Mol Sci. 2022 Jul 5;23(13):7471. doi: 10.3390/ijms23137471.
5
Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.
Chem Rev. 2018 Feb 28;118(4):1599-1663. doi: 10.1021/acs.chemrev.7b00504. Epub 2018 Jan 11.
6
Theranostic DNAzymes.
Theranostics. 2017 Feb 23;7(4):1010-1025. doi: 10.7150/thno.17736. eCollection 2017.
7
Preparation of a disulfide-linked precipitative soluble support for solution-phase synthesis of trimeric oligodeoxyribonucleotide 3´-(2-chlorophenylphosphate) building blocks.
Beilstein J Org Chem. 2015 Sep 7;11:1553-60. doi: 10.3762/bjoc.11.171. eCollection 2015.
8
Positive Modulation of the Glycine Receptor by Means of Glycine Receptor-Binding Aptamers.
J Biomol Screen. 2015 Oct;20(9):1112-23. doi: 10.1177/1087057115590575. Epub 2015 Jun 12.
9
Recombinant adeno-associated virus serotype 9 with p65 ribozyme protects H9c2 cells from oxidative stress through inhibiting NF-κB signaling pathway.
J Geriatr Cardiol. 2014 Dec;11(4):311-5. doi: 10.11909/j.issn.1671-5411.2014.04.006.
10
Therapeutic regulation of gene expression in the inner ear using RNA interference.
Adv Otorhinolaryngol. 2009;66:13-36. doi: 10.1159/000218205. Epub 2009 Jun 2.
本文引用的文献
1
Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME) in healthy volunteers.
J Clin Pharmacol. 2000 Dec;40(12 Pt 2):1462-9.
2
Acute toxicology and pharmacokinetic assessment of a ribozyme (ANGIOZYME) targeting vascular endothelial growth factor receptor mRNA in the cynomolgus monkey.
Antisense Nucleic Acid Drug Dev. 2000 Jun;10(3):153-62. doi: 10.1089/oli.1.2000.10.153.
3
Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors.
Clin Cancer Res. 2000 May;6(5):2094-103.
4
Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes.
Hepatology. 2000 Mar;31(3):769-76. doi: 10.1002/hep.510310331.
5
Pharmacokinetics of an antiangiogenic ribozyme (ANGIOZYME) in the mouse.
Antisense Nucleic Acid Drug Dev. 1999 Jun;9(3):271-7. doi: 10.1089/oli.1.1999.9.271.
6
Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA.
Nucleic Acids Res. 1999 Jul 1;27(13):2569-77. doi: 10.1093/nar/27.13.2569.
7
Hepatitis C: the clinical spectrum of disease.
Hepatology. 1997 Sep;26(3 Suppl 1):15S-20S. doi: 10.1002/hep.510260703.
8
Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides.
Anticancer Drug Des. 1997 Jul;12(5):395-408.
9
Poliovirus chimeras replicating under the translational control of genetic elements of hepatitis C virus reveal unusual properties of the internal ribosomal entry site of hepatitis C virus.
Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1412-7. doi: 10.1073/pnas.93.4.1412.
10
Vascular endothelial growth factor, a potent and selective angiogenic agent.
J Biol Chem. 1996 Jan 12;271(2):603-6. doi: 10.1074/jbc.271.2.603.
Zotero 插件